First in Human, Single Ascending Dose Study
NCT05844592
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Ulcerative Colitis
Interventions
DRUG:
INV-101
Sponsor
Innovo Therapeutics, Inc.